Glaukos (GKOS) Short term Debt (2014 - 2021)

Glaukos (GKOS) posted quarterly Short term Debt of $279.3 million for Q2 2021, little changed quarter-over-quarter from $279.0 million in Q1 2021.

Glaukos (GKOS) Short term Debt (2014 - 2021) Analysis & Trends

Glaukos (GKOS) has reported Short term Debt for 5 consecutive years, with $279.3 million the latest figure, recorded in Q2 2021.

In Q2 2021, Short term Debt changed N/A year-over-year to $279.3 million; the TTM figure through Jun 2021 stood at $279.3 million (changed N/A YoY), while the FY2020 annual figure was $89.2 million, changed N/A from the prior year.
Short term Debt was little changed at $279.3 million in Q2 2021 per GKOS's latest filing, from $279.0 million in the prior quarter.
Across five years, Short term Debt topped out at $279.3 million in Q2 2021 and bottomed at $89.2 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.24 Bn	193.64 Bn	7.27 Bn
2	Stryker	128.63 Bn	125.15 Bn	4.50 Bn
3	Medtronic	119.19 Bn	109.97 Bn	6.41 Bn
4	Boston Scientific	73.51 Bn	72.97 Bn	3.85 Bn
5	Edwards Lifesciences	52.11 Bn	47.85 Bn	1.35 Bn
6	Dexcom	34.64 Bn	32.70 Bn	830.00 Mn
7	GE HealthCare Technologies	34.01 Bn	31.90 Bn	2.18 Bn
8	Koninklijke Philips	26.40 Bn	23.08 Bn	4.55 Bn
9	Steris	23.14 Bn	22.65 Bn	684.20 Mn
10	Glaukos	11.08 Bn	10.96 Bn	151.59 Mn

Download Data